Search
EHA’s advocacy for hematology continues
The EHA Board has recently approved five position papers which formulate EHA’s key lobbying priorities:
Support for hematology research in Horizon 2020 (and future EU research funding programs)
Access to treatment for patients with blood disorders
EU collaboration to reduce the prices…
Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients
Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.
Read moreMajor bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…
Publications
For the subgroup Rare hereditary blood cancers:
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.
GAPP Joint Action
Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.
Read moreMeet our first Physician Scientist Research Grant winner
In 2018 the Physician Scientist Research Grant was awarded for the first time.
Read more